<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00721955</url>
  </required_header>
  <id_info>
    <org_study_id>AMDC-004-302</org_study_id>
    <nct_id>NCT00721955</nct_id>
  </id_info>
  <brief_title>Staccato Loxapine in Agitated Patients With Bipolar Disorder</brief_title>
  <official_title>A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multi-Dose Efficacy and Safety Study of Staccato® Loxapine for Inhalation in Patients With Bipolar I Disorder and Acute Agitation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexza Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alexza Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 3 safety and efficacy study of Staccato Loxapine in the treatment of acute agitation in
      bipolar 1 disorder patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an in-clinic, multi-center, randomized, double-blind, placebo-controlled study of 2
      dose levels of Staccato Loxapine, 5 and 10 mg. Patients may receive up to 3 doses of study
      drug in a 24-hour period, depending on their clinical status. The primary endpoint is the
      change from baseline in the PANSS (Positive and Negative Symptom Scale) Excited Component
      (also known as PEC) score, performed at 2 hours after the first dose.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in PANSS Excited Component (PEC) Score From Baseline Following Dose #1 of Staccato Loxapine, Compared With Placebo</measure>
    <time_frame>Baseline and 2 hours</time_frame>
    <description>The Positive and Negative Syndrome Scale-Excited Component (PANSS-EC) comprises 5 items associated with agitation: poor impulse control, tension, hostility, uncooperativeness, and excitement; each scored 1 (min) to 7 (max). The PANSS-EC, the sum of these 5 subscales, thus ranges from 5 to 35. Individuals were eligible if they had a PANSS-EC of ≥14 (out of 35) and a score ≥4 (out of 7) on at least 1 of the 5 items.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression-Improvement (CGI-I) Score Following Dose #1 of Staccato Loxapine, Compared With Placebo</measure>
    <time_frame>Baseline and 2 hours</time_frame>
    <description>Clinical Global Impression- Improvement (CGI-I) scores ranged from 1 to 7: 0=not assessed (missing), 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CGI-I Responders</measure>
    <time_frame>Baseline and 2 hours</time_frame>
    <description>Frequency of response based on the CGI-I (defined as achieving a CGI-I score of 1 or 2 at 2 hours after administration of the inhalation)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">314</enrollment>
  <condition>Bipolar I Disorder</condition>
  <arm_group>
    <arm_group_label>Inhaled Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Inhaled Staccato Placebo, may repeat after 2 hours x 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Inhaled Loxapine 5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inhaled Staccato Loxapine 5 mg, may repeat after 2 hours x 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Inhaled Loxapine 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inhaled Staccato Loxapine 10 mg, may repeat after 2 hours x 2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inhaled Placebo</intervention_name>
    <description>Inhaled loxapine Placebo, may repeat after 2 hours x 2</description>
    <arm_group_label>Inhaled Placebo</arm_group_label>
    <other_name>Staccato Placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inhaled loxapine 5 mg</intervention_name>
    <description>Inhaled Staccato loxapine 5 mg, may repeat after 2 hours x 2</description>
    <arm_group_label>Inhaled Loxapine 5 mg</arm_group_label>
    <other_name>ADASUVE 5 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inhaled loxapine 10 mg</intervention_name>
    <description>Inhaled Staccato loxapine 10 mg, may repeat after 2 hours x 2</description>
    <arm_group_label>Inhaled Loxapine 10 mg</arm_group_label>
    <other_name>ADASUVE 10 mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female adult patients with bipolar 1 disorder and acute agitation

        Exclusion Criteria:

          -  Agitation caused primarily by acute intoxication

          -  History of drug or alcohol dependence

          -  Treatment with benzodiazepines or other hypnotics within 4 hours prior to study drug
             administration
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert S Fishman, MD</last_name>
    <role>Study Director</role>
    <affiliation>Alexza Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Synergy Escondido</name>
      <address>
        <city>Escondido</city>
        <state>California</state>
        <zip>92025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Collaborative NeuroScience Network, Inc.</name>
      <address>
        <city>Garden Grove</city>
        <state>California</state>
        <zip>92845</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta Center for Medical Research</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FutureSearch Trials</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Claghorn-Lesem Research Clinic</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77008</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Clinical Research Center</name>
      <address>
        <city>Bellevue</city>
        <state>Washington</state>
        <zip>98004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Kwentus J, Riesenberg RA, Marandi M, Manning RA, Allen MH, Fishman RS, Spyker DA, Kehne JH, Cassella JV. Rapid acute treatment of agitation in patients with bipolar I disorder: a multicenter, randomized, placebo-controlled clinical trial with inhaled loxapine. Bipolar Disord. 2012 Feb;14(1):31-40. doi: 10.1111/j.1399-5618.2011.00975.x.</citation>
    <PMID>22329470</PMID>
  </reference>
  <verification_date>October 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 23, 2008</study_first_submitted>
  <study_first_submitted_qc>July 24, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 25, 2008</study_first_posted>
  <results_first_submitted>March 13, 2017</results_first_submitted>
  <results_first_submitted_qc>May 30, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">June 29, 2017</results_first_posted>
  <last_update_submitted>June 28, 2017</last_update_submitted>
  <last_update_submitted_qc>June 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bipolar 1 disorder,</keyword>
  <keyword>agitation,</keyword>
  <keyword>acute,</keyword>
  <keyword>treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Loxapine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>IPD submitted to regulatory authorities. Others may contact Alexza Pharmaceuticals, Inc. Please send your request to ClinicalTrialsInfo@alexza.com</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Inhaled Placebo</title>
          <description>Inhaled Staccato Placebo, may repeat after 2 hours x 2
Inhaled Placebo: Inhaled loxapine Placebo, may repeat after 2 hours x 2</description>
        </group>
        <group group_id="P2">
          <title>Inhaled Loxapine 5 mg</title>
          <description>Inhaled Staccato Loxapine 5 mg, may repeat after 2 hours x 2
Inhaled loxapine 5 mg: Inhaled Staccato loxapine 5 mg, may repeat after 2 hours x 2</description>
        </group>
        <group group_id="P3">
          <title>Inhaled Loxapine 10 mg</title>
          <description>Inhaled Staccato Loxapine 10 mg, may repeat after 2 hours x 2
Inhaled loxapine 10 mg: Inhaled Staccato loxapine 10 mg, may repeat after 2 hours x 2</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="105"/>
                <participants group_id="P2" count="104"/>
                <participants group_id="P3" count="105"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="105"/>
                <participants group_id="P2" count="104"/>
                <participants group_id="P3" count="103"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety Population</population>
      <group_list>
        <group group_id="B1">
          <title>Inhaled Placebo</title>
          <description>Inhaled Staccato Placebo, may repeat after 2 hours x 2
Inhaled Placebo: Inhaled loxapine Placebo, may repeat after 2 hours x 2</description>
        </group>
        <group group_id="B2">
          <title>Inhaled Loxapine 5 mg</title>
          <description>Inhaled Staccato Loxapine 5 mg, may repeat after 2 hours x 2
Inhaled loxapine 5 mg: Inhaled Staccato loxapine 5 mg, may repeat after 2 hours x 2</description>
        </group>
        <group group_id="B3">
          <title>Inhaled Loxapine 10 mg</title>
          <description>Inhaled Staccato Loxapine 10 mg, may repeat after 2 hours x 2
Inhaled loxapine 10 mg: Inhaled Staccato loxapine 10 mg, may repeat after 2 hours x 2</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="105"/>
            <count group_id="B2" value="104"/>
            <count group_id="B3" value="105"/>
            <count group_id="B4" value="314"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="105"/>
                    <measurement group_id="B2" value="104"/>
                    <measurement group_id="B3" value="105"/>
                    <measurement group_id="B4" value="314"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.6" spread="9.82"/>
                    <measurement group_id="B2" value="41.2" spread="9.63"/>
                    <measurement group_id="B3" value="40.5" spread="9.80"/>
                    <measurement group_id="B4" value="40.7" spread="9.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="57"/>
                    <measurement group_id="B3" value="52"/>
                    <measurement group_id="B4" value="158"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="53"/>
                    <measurement group_id="B4" value="156"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="105"/>
                    <measurement group_id="B2" value="104"/>
                    <measurement group_id="B3" value="105"/>
                    <measurement group_id="B4" value="314"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in PANSS Excited Component (PEC) Score From Baseline Following Dose #1 of Staccato Loxapine, Compared With Placebo</title>
        <description>The Positive and Negative Syndrome Scale–Excited Component (PANSS–EC) comprises 5 items associated with agitation: poor impulse control, tension, hostility, uncooperativeness, and excitement; each scored 1 (min) to 7 (max). The PANSS-EC, the sum of these 5 subscales, thus ranges from 5 to 35. Individuals were eligible if they had a PANSS-EC of ≥14 (out of 35) and a score ≥4 (out of 7) on at least 1 of the 5 items.</description>
        <time_frame>Baseline and 2 hours</time_frame>
        <population>ITT Population with LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Inhaled Placebo</title>
            <description>Inhaled Staccato Placebo, may repeat after 2 hours x 2
Inhaled Placebo: Inhaled loxapine Placebo, may repeat after 2 hours x 2</description>
          </group>
          <group group_id="O2">
            <title>Inhaled Loxapine 5 mg</title>
            <description>Inhaled Staccato Loxapine 5 mg, may repeat after 2 hours x 2
Inhaled loxapine 5 mg: Inhaled Staccato loxapine 5 mg, may repeat after 2 hours x 2</description>
          </group>
          <group group_id="O3">
            <title>Inhaled Loxapine 10 mg</title>
            <description>Inhaled Staccato Loxapine 10 mg, may repeat after 2 hours x 2
Inhaled loxapine 10 mg: Inhaled Staccato loxapine 10 mg, may repeat after 2 hours x 2</description>
          </group>
        </group_list>
        <measure>
          <title>Change in PANSS Excited Component (PEC) Score From Baseline Following Dose #1 of Staccato Loxapine, Compared With Placebo</title>
          <description>The Positive and Negative Syndrome Scale–Excited Component (PANSS–EC) comprises 5 items associated with agitation: poor impulse control, tension, hostility, uncooperativeness, and excitement; each scored 1 (min) to 7 (max). The PANSS-EC, the sum of these 5 subscales, thus ranges from 5 to 35. Individuals were eligible if they had a PANSS-EC of ≥14 (out of 35) and a score ≥4 (out of 7) on at least 1 of the 5 items.</description>
          <population>ITT Population with LOCF</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="104"/>
                <count group_id="O3" value="105"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.9" spread="4.77"/>
                    <measurement group_id="O2" value="-8.1" spread="4.90"/>
                    <measurement group_id="O3" value="-9.0" spread="4.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>LS mean was used in the primary efficacy analysis</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>p-values (adjusted) using Dunnett's t-test in main effects ANCOVA model</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>p-values (adjusted) using Dunnett's t-test in main effects ANCOVA model</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>p-values (adjusted) using Dunnett's t-test in main effects ANCOVA model</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Global Impression-Improvement (CGI-I) Score Following Dose #1 of Staccato Loxapine, Compared With Placebo</title>
        <description>Clinical Global Impression- Improvement (CGI-I) scores ranged from 1 to 7: 0=not assessed (missing), 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse.</description>
        <time_frame>Baseline and 2 hours</time_frame>
        <population>ITT Population with LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Inhaled Placebo</title>
            <description>Inhaled Staccato Placebo, may repeat after 2 hours x 2
Inhaled Placebo: Inhaled loxapine Placebo, may repeat after 2 hours x 2</description>
          </group>
          <group group_id="O2">
            <title>Inhaled Loxapine 5 mg</title>
            <description>Inhaled Staccato Loxapine 5 mg, may repeat after 2 hours x 2
Inhaled loxapine 5 mg: Inhaled Staccato loxapine 5 mg, may repeat after 2 hours x 2</description>
          </group>
          <group group_id="O3">
            <title>Inhaled Loxapine 10 mg</title>
            <description>Inhaled Staccato Loxapine 10 mg, may repeat after 2 hours x 2
Inhaled loxapine 10 mg: Inhaled Staccato loxapine 10 mg, may repeat after 2 hours x 2</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Global Impression-Improvement (CGI-I) Score Following Dose #1 of Staccato Loxapine, Compared With Placebo</title>
          <description>Clinical Global Impression- Improvement (CGI-I) scores ranged from 1 to 7: 0=not assessed (missing), 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse.</description>
          <population>ITT Population with LOCF</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="104"/>
                <count group_id="O3" value="105"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" spread="0.99"/>
                    <measurement group_id="O2" value="2.1" spread="1.10"/>
                    <measurement group_id="O3" value="1.9" spread="1.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>LS mean was used in the primary efficacy analysis</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>p-values (adjusted) using Dunnett's t-test in main effects ANCOVA model</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>-values (adjusted) using Dunnett's t-test in main effects ANCOVA model</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CGI-I Responders</title>
        <description>Frequency of response based on the CGI-I (defined as achieving a CGI-I score of 1 or 2 at 2 hours after administration of the inhalation)</description>
        <time_frame>Baseline and 2 hours</time_frame>
        <population>ITT Population with LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Inhaled Placebo</title>
            <description>Inhaled Staccato Placebo, may repeat after 2 hours x 2
Inhaled Placebo: Inhaled loxapine Placebo, may repeat after 2 hours x 2</description>
          </group>
          <group group_id="O2">
            <title>Inhaled Loxapine 5 mg</title>
            <description>Inhaled Staccato Loxapine 5 mg, may repeat after 2 hours x 2
Inhaled loxapine 5 mg: Inhaled Staccato loxapine 5 mg, may repeat after 2 hours x 2</description>
          </group>
          <group group_id="O3">
            <title>Inhaled Loxapine 10 mg</title>
            <description>Inhaled Staccato Loxapine 10 mg, may repeat after 2 hours x 2
Inhaled loxapine 10 mg: Inhaled Staccato loxapine 10 mg, may repeat after 2 hours x 2</description>
          </group>
        </group_list>
        <measure>
          <title>CGI-I Responders</title>
          <description>Frequency of response based on the CGI-I (defined as achieving a CGI-I score of 1 or 2 at 2 hours after administration of the inhalation)</description>
          <population>ITT Population with LOCF</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="104"/>
                <count group_id="O3" value="105"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="69"/>
                    <measurement group_id="O3" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From informed consent through 30 days after last treatment</time_frame>
      <desc>AEs were recorded when identified by the study center staff or volunteered by a patient.</desc>
      <group_list>
        <group group_id="E1">
          <title>Inhaled Placebo</title>
          <description>Inhaled Staccato Placebo, may repeat after 2 hours x 2
Inhaled Placebo: Inhaled loxapine Placebo, may repeat after 2 hours x 2</description>
        </group>
        <group group_id="E2">
          <title>Inhaled Loxapine 5 mg</title>
          <description>Inhaled Staccato Loxapine 5 mg, may repeat after 2 hours x 2
Inhaled loxapine 5 mg: Inhaled Staccato loxapine 5 mg, may repeat after 2 hours x 2</description>
        </group>
        <group group_id="E3">
          <title>Inhaled Loxapine 10 mg</title>
          <description>Inhaled Staccato Loxapine 10 mg, may repeat after 2 hours x 2
Inhaled loxapine 10 mg: Inhaled Staccato loxapine 10 mg, may repeat after 2 hours x 2</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="105"/>
                <counts group_id="E2" events="18" subjects_affected="18" subjects_at_risk="104"/>
                <counts group_id="E3" events="18" subjects_affected="18" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="105"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="104"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="105"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="104"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Sedation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="105"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="104"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Because of the need to provide informed consent, the types of patients enrolled in the study may not have been representative of the most severely agitated patients who present for emergency care.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Chief Scientific Officer</name_or_title>
      <organization>Alexza Pharmaceuticals, Inc</organization>
      <phone>650.944.7777</phone>
      <email>:jcassella@alexza.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

